Laurus Labs Share Price

₹ 2,320.40

-₹2.60 (-0.11%)
1D
Last updated 04 Nov, 2026, 13:02 IST
NSE: LAURUSLABS
|
Pharmaceuticals

Laurus Labs Share Price Today

As of 4 Nov 2026, Laurus Labs share price is ₹2,320.40. The stock opened at ₹2,291.00, compared to its previous close of ₹2,323.00. During today's trading session, Laurus Labs share price moved in the range of ₹2,285.60 to ₹2,343.90, with an average price of ₹2,314.75 for the day. Looking at its last 52-week, the stock has touched a low of ₹917.95 and a high of ₹2,441.90. On the performance front, Laurus Labs share price has increased by 111.00% over the last six months and is up 138.16% on a year-on-year basis.

Share price over the last 1 day rose from 2306.30 to 2321.00, ranging between 2294.00 and 2343.50.
₹2,285.60
0.11% down today
₹2,343.90
1D LOW
1D HIGH

Laurus Labs Stock Insights

Latest Earning
Op Profit TrendUp by 22.95% QoQ
Latest Earning
Net Profit TrendUp by 20.65% QoQ
Latest Earning
Revenue TrendUp by 9.03% QoQ
Stock Performance
OutperformingBeat Nifty by 15.18 % in last 1 month
Shareholding Pattern
PromoterPromoter decreased stake by 0.02%
Shareholding Pattern
DIIDII increased stake by 0.28%
Shareholding Pattern
FIIFII increased stake by 10.13%
Technical Indicators
Volume SpikeVolume is 52.0% above 20-day average on 1 Day interval.
Laurus Labs stock performance
Open₹2,291.00
High₹2,343.90
Low₹2,285.60
Prev. close₹2,323.00
Laurus Labs trading activity
Volume16,23,711
Average traded price₹2,321.17
Last traded time01:02:41 04 Nov
Last traded quantity65
Circuit
L
H
₹2,090.70
₹2,555.30
52-week
L
H
₹917.95
₹2,441.90
Mkt Cap Cr
1,26,811.28
P/E
94.08
P/B
20.68
ROA
11.58%
ROE
22.11%
ROCE
20.91%
Quick Ratio
0.68
EV/EBITDA
53.48

Based on fundamentals, this stock's

Performance: 5 out of 5, Excellent
Performance
Excellent
Laurus Labs outperforming all market indices
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Laurus Labs appears overvalued compared to its peers
Earnings: 5 out of 5, Excellent
Earnings
Excellent
Laurus Labs revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,24,202.4238.614.759.61%13.79%18.65%2.3122.27
Divis Laboratories2,64,141.2490.3115.7614.6%15.32%19.56%3.558.97
Torrent Pharmaceuticals1,74,402.4784.09.64.7%11.42%11.37%0.7533.48
Zydus Lifesciences1,23,685.4926.934.568.57%18.59%17.35%0.9116.42
Dr. Reddy's Laboratories1,11,868.0340.542.884.79%7.21%8.58%1.3519.05
Cipla1,11,647.7239.123.156.6%8.18%10.8%2.521.03
Mankind Pharma1,02,315.4045.25.827.82%12.76%14.68%0.7424.9
Aurobindo Pharma96,951.1826.132.566.34%9.25%11.76%1.1512.38
Lupin91,300.8316.574.114.47%23.76%24.88%1.429.76
Glenmark Pharma67,395.2537.766.469.03%28.08%32.7%1.2319.87

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Laurus Labs Company Background

ISIN
INE947Q01028
Sector Market Cap
₹ 126,811.28 Cr

Laurus Labs is an Indian pharmaceutical and biotechnology company. It is headquartered in Hyderabad and was founded in 2005.

Initially founded as a CRAMS (contract research and manufacturing services) enterprise, the company swiftly diversified into antiretroviral drugs (ARVs). Within five years, it transitioned into a respected active pharmaceutical ingredients (API) focused company. Another half-decade later, Laurus Labs expanded into a fully integrated pharmaceutical company.

The market capitalisation of Laurus Labs Limited is over ₹22,600 crore as of January 10, 2024. Laurus Labs share price has gained over 18% in the last three years.

Business operations

Laurus Labs specialises in the development, production and distribution of pharmaceutical ingredients and their related intermediates worldwide. It also offers a range of services to the global pharmaceutical industry, including drug discovery, medicinal chemistry, lead optimisation, process development, scale-up, safety assessment, formulation development and analytical chemistry services for its clientele.

Laurus Labs operates through three primary business segments. Firstly, Laurus Generics focuses on the development, manufacturing, and sale of APIs and advanced intermediates, along with oral solid formulations and finished dosage forms (FDFs). Secondly, Laurus Synthesis specialises in key starting materials (KSM), intermediates and APIs, particularly for new chemical entities (NCEs). Laurus Bio concentrates on recombinant products, producing animal-origin-free products for safer and virus-free bio-manufacturing processes.

Laurus Limited collaborates with the top 10 global generic pharmaceutical companies, distributing its APIs across 56 countries. The company concentrates primarily on developing anti-retroviral, Hepatitis C and oncology drugs.

Laurus Limited is also deeply involved in the research and development (R&D) in high-growth potential areas. With a total of 322 filed patents, it currently owns 203. Over its operational tenure, Laurus Limited has successfully brought more than 60 products to market, spread across three distinct business segments: Generics API, generics finished dosage form (FDF) and synthesis.

The company has over 55 state-of-the-art R&D labs strategically positioned in India and the US. It manufactures a staggering 90-plus APIs across ten cutting-edge manufacturing facilities which have over 7 million litres of reactor capacity. The company has a workforce comprising over 5,000 professionals, among which 800-plus are dedicated research scientists. This team serves more than 200 customers spread across 56 countries.

Laurus Labs has API manufacturing facilities in Visakhapatnam, an FDF drug manufacturing facility situated in Achutapuram and a research and development centre at IKP Knowledge Park in Hyderabad. The Hyderabad centre is also approved by the Department of Scientific and Industrial Research, Ministry of Science and Technology of India (DSIR).

With its manufacturing and R&D, Laurus is among the global leaders in supplying anti-retroviral APIs and intermediates. Its cost-effective technologies contribute to improving access to affordable medication worldwide. Oncology is Laurus Limited's key strength. It offers an extensive range of APIs in this domain. Laurus consistently expands its portfolio and its focus extends to molecules in diabetes, ophthalmology and cardiovascular therapy areas.

Laurus Labs Financial Highlights

  • Revenue: Laurus Labs reported revenue of ₹6,867.85 crore in FY26 vs ₹5,629.06 crore in FY25. It showed an increase of 22.01% on a yearly basis.
  • Operating Profit: Laurus Labs reported an operating profit of ₹1,181.88 crore in FY26 vs ₹484.29 crore in FY25. It showed an increase of 144.04% on a year-on-year basis.
  • Net Profit: Laurus Labs reported a net profit of ₹889.85 crore in FY26 vs ₹354.41 crore in FY25. It showed an increase of 151.08% on a yearly basis.

Laurus Labs Quarterly Result Highlights

  • Laurus Labs reported revenue of ₹2,219.38 crore in Sep 2026, compared with ₹2,035.49 crore in Jun 2026, representing an increase of 9.03% on a quarter-on-quarter (QoQ) basis.
  • Laurus Labs reported an operating profit of ₹591.82 crore in Sep 2026, compared with ₹481.36 crore in Jun 2026, representing an increase of 22.95% on a quarter-on-quarter (QoQ) basis.
  • Laurus Labs reported a profit of ₹436.74 crore in Sep 2026, compared with ₹361.99 crore in Jun 2026, reflecting an increase of 20.65% on a QoQ basis.
  • The earnings per share (EPS) of Laurus Labs stood at ₹16.47 during Sep 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
27.47%
FII
30.84%
Other DII
3.60%
Retail and other
29.83%
Mutual funds
8.26%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 202526.52%
Mar 202625.82%
Jun 202628.00%
Sep 202630.84%

Laurus Labs Investment Returns

1 day
-1.06%
1 week
+8.45%
1 month
+17.09%
1 year
+138.16%
3 years
+537.66%
5 years
+369.25%

Laurus Labs Share Price History

Laurus Labs share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
03 Nov 26
₹2,350.10 / ₹2,323.00
-1.06%
02 Nov 26
₹2,406.00 / ₹2,348.00
-2.39%
30 Oct 26
₹2,246.60 / ₹2,405.50
+7.20%
29 Oct 26
₹2,190.00 / ₹2,244.00
+2.85%
Show more

Laurus Labs Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹6,812.90₹5,553.96₹5,040.83₹6,040.55
Other Income₹54.95₹75.10₹26.34₹6.00
Total Revenue₹6,867.85₹5,629.06₹5,067.17₹6,046.55
Total Expenses₹5,685.97₹5,144.77₹4,830.81₹4,937.61
Profit Before Tax₹1,181.88₹484.29₹236.36₹1,108.94
Tax₹292.03₹129.88₹68.15₹312.30
Profit After Tax₹889.85₹354.41₹168.21₹796.64
EPS - Basic₹16.47₹6.65₹2.98₹14.69
EPS - Diluted₹16.45₹6.64₹2.97₹14.64

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹1,181.88₹484.29₹236.36₹1,108.94
Income before WC changes₹1,892.28₹1,113.79₹799.28₹1,594.65
Change in Assets-₹561.83-₹542.78-₹274.91-₹136.09
Change in Liabilities₹586.91₹168.18₹245.89-₹179.17
Change in WC₹25.08-₹374.60-₹29.02-₹315.26
Cash flow from Operations₹1,623.50₹601.65₹665.69₹993.90
Cash flow from Investing-₹1,088.66-₹681.72-₹822.42-₹996.06
Cash flow from Financing-₹524.72₹39.28₹249.83-₹26.64
Total Cash Flow₹10.12-₹40.79₹93.10-₹28.80
Cash (Start of the year)₹99.54₹138.94₹45.67₹75.35
Cash (End of the year)₹112.66₹99.54₹138.94₹45.67

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹5,681.98₹5,003.25₹4,552.06₹4,198.72
Current Assets₹4,829.21₹4,332.32₹3,834.97₹3,461.68
Total Assets₹10,511.19₹9,335.57₹8,387.03₹7,660.40
Current Liabilities₹3,635.43₹3,539.72₹3,112.28₹2,432.26
Net Current Asset₹1,193.78₹792.60₹722.69₹1,029.42
Non-Current Liabilities₹1,444.40₹1,193.33₹1,159.18₹1,179.48
Equity Capital₹5,431.36₹4,602.52₹4,115.57₹4,048.66
Total Equity & Liabilities₹10,511.19₹9,335.57₹8,387.03₹7,660.40

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹6,089.07₹5,216.98₹4,812.39₹5,773.45
Other Income₹77.43₹100.47₹47.42₹15.95
Total Revenue₹6,166.50₹5,317.45₹4,859.81₹5,789.40
Total Expenses₹5,172.41₹4,813.64₹4,558.34₹4,737.97
Profit Before Tax₹994.09₹503.81₹301.47₹1,051.43
Tax₹253.61₹123.42₹77.77₹291.05
Profit After Tax₹740.48₹380.39₹223.70₹760.38
EPS - Basic₹13.72₹7.06₹4.15₹14.14
EPS - Diluted₹13.70₹7.05₹4.15₹14.09

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹994.09₹503.81₹301.47₹1,051.43
Income before WC changes₹1,544.34₹1,002.44₹779.79₹1,493.94
Change in Assets-₹399.76-₹526.54-₹310.31-₹87.25
Change in Liabilities₹525.93₹198.55₹287.04-₹257.01
Change in WC₹126.17-₹327.99-₹23.27-₹344.26
Cash flow from Operations₹1,384.95₹540.06₹658.54₹881.55
Cash flow from Investing-₹847.06-₹591.65-₹756.74-₹735.27
Cash flow from Financing-₹550.74₹59.32₹139.41-₹185.19
Total Cash Flow-₹12.85₹7.73₹41.21-₹38.91
Cash (Start of the year)₹50.36₹42.63₹1.42₹40.33
Cash (End of the year)₹37.51₹50.36₹42.63₹1.42

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹5,177.44₹4,579.97₹4,150.37₹3,786.70
Current Assets₹4,362.59₹4,006.78₹3,517.11₹3,171.26
Total Assets₹9,540.03₹8,586.75₹7,667.48₹6,957.96
Current Liabilities₹3,257.91₹3,162.04₹2,735.79₹2,106.32
Net Current Asset₹1,104.68₹844.74₹781.32₹1,064.94
Non-Current Liabilities₹1,030.18₹860.76₹724.64₹794.82
Equity Capital₹5,251.94₹4,563.95₹4,207.05₹4,056.82
Total Equity & Liabilities₹9,540.03₹8,586.75₹7,667.48₹6,957.96
* All values are in INR Crore
Laurus Labs market depth
Bid quantityBid priceAsk priceAsk quantity
592320.42320.534
10232320.32320.820
10122320.22321347
832320.12321.127
20723202321.2121
Total bid quantity2,384
Total ask quantity549
Laurus Labs technical summary
Bearish indicators2
Neutral indicators5
Bullish indicators1
OverallSlightly Bearish
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
68.92
Neutral
ATR (14)
81.56
Neutral
STOCH(9,6)
76.61
Neutral
STOCH RSI (14)
69.75
Neutral
ADX(9)
32.27
Bearish
UO(9)
74.64
Bearish
ROC(12)
15.09
Bullish
WillR(14)
-23.39
Neutral
Period
Simple value
Exponential vaue
5D
2300.48
2289.56
10D
2168.83
2216.14
20D
2106.94
2137.14
50D
2002.75
2006.85
100D
1808.96
1829.57
Volume trend — traded volume by day
4 Nov16L
3 Nov40L
2 Nov30L
30 Oct79L
29 Oct29L
28 Oct22L
Average36L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Laurus Labs
Pharmaceuticals
Add Stock
Add Another

Laurus Labs Returns Calculator

Ex-date: 08 May 2026

Laurus Labs Latest News

4 days ago
Market weekly wrap: SENSEX, NIFTY50 rise 2%; NIFTY Smallcap 100 jumps 4%, Trent leads rally
1 month ago
Sun Pharma, Mankind Pharma, Wockhardt, other pharma stocks surge up to 6%, Nifty Pharma up 1.5%; key things to know
1 month ago
Sun Pharma to Zydus: Healthcare stocks outperform broader market despite price pressure; can they sustain growth?
1 month ago
Paytm, Laurus Labs, Raymond, Chennai Petro hit 52-week high despite weak market sentiment; check full list
2 months ago
Sun Pharma, Laurus Labs, Mankind Pharma, others drag Nifty Pharma down 1.6%; here’s what investors should know
2 months ago
Lenskart to Adani Energy: Here’s how MSCI rebalancing stocks are trading ahead of August 31 deadline
2 months ago
Laurus Labs to TVS Motor: 6 stocks that hit all-time highs on Wednesday; check full list
2 months ago
JSW Steel to Lenskart: 5 Nifty 500 stocks near 52-week highs with increasing FII interest
3 months ago
IndiGo, Eternal, Senco Gold among top 10 high-volume stocks amid market rebound; check full list
3 months ago
Torrent Pharma, Mankind, Cipla, others lift Nifty Pharma 1.8%; why are pharma stocks rising in weak market?
Showing news item 1 of 10

Top Gainers

GMDCLTD Share Price
₹466.00
+40.4 (+9.49%)
EQUITASBNK Share Price
₹56.96
+4.31 (+8.19%)
SAREGAMA Share Price
₹606.45
+44.25 (+7.87%)
LINDEINDIA Share Price
₹6272.50
+424 (+7.25%)
UNOMINDA Share Price
₹1199.60
+75.1 (+6.68%)
See more

Top Losers

SKFINDIA Share Price
₹1392.20
-79.7 (-5.41%)
AIAENG Share Price
₹3226.80
-162.9 (-4.81%)
ALKYLAMINE Share Price
₹1585.30
-73.5 (-4.43%)
ZYDUSLIFE Share Price
₹1191.00
-49.6 (-4%)
ASAHIINDIA Share Price
₹958.00
-33.45 (-3.37%)
See more

Laurus Labs Share Price FAQs

Please be aware that Laurus Labs stock prices are subject to continuous fluctuations due to various factors.